zimmytws
Biotechs equivalent to Gilead (NASDAQ:GILD) and Vertex Pharma (NASDAQ:VRTX), with a excessive native tax invoice, a heavy U.S.-based manufacturing footprint, and an IP rights portfolio, look considerably insulated from potential pharma tariffs, The Wall Avenue Journal stated in a current report.
